Cgp 43371

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412653

CAS#: 123036-23-7

Description: Cgp 43371 is a highly lipophilic derivative of rifampicin that was undergoing preclinical investigation by Novartis as an antihyperlipidaemic agent.

Chemical Structure

img
Cgp 43371
CAS# 123036-23-7
Instruction

Theoretical Analysis

MedKoo Cat#: 412653
Name: Cgp 43371
CAS#: 123036-23-7
Chemical Formula: C56H81N3O12
Exact Mass: 987.58
Molecular Weight: 988.270
Elemental Analysis: C, 68.06; H, 8.26; N, 4.25; O, 19.43

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Cgp 43371; Cgp43371; Cgp-43371

IUPAC/Chemical Name: Rifamycin, N,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)

InChi Key: QFULYWYYYANMNL-LIUKAILQSA-N

InChi Code: 1S/C56H73N3O12/c1-28-25-31(4)38(32(5)26-28)27-58-20-22-59(23-21-58)44-43-51-41-40(47(44)63)42-50(36(9)49(41)70-54(65)55(11,12)13)71-56(14,52(42)64)67-24-19-39(66-15)33(6)48(68-37(10)60)35(8)46(62)34(7)45(61)29(2)17-16-18-30(3)53(57-43)69-51/h16-19,24-26,29,33-35,39,45-46,48,61-63H,20-23,27H2,1-15H3/b17-16+,24-19+,30-18-/t29-,33+,34+,35+,39-,45-,46+,48+,56-/m0/s1

SMILES Code: CO[C@H]1C=CO[C@]2(OC3C(C(C4c5oc(C(C)=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(C)=O)C)O)C)O)C)nc5C(C(C4C3C2=O)O)N6CCN(CC6)Cc7c(C)cc(C)cc7C)OC(C(C)(C)C)=O)C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 988.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gibson JC, Lee WH, Stephan ZF. The ansamycins: a novel class of hypolipidemic agents with a high affinity for lipoproteins. Atherosclerosis. 1995 Jan 6;112(1):47-57. doi: 10.1016/0021-9150(95)90369-w. PMID: 7772066.

2: Sun JX, Walter B, Sandefer EP, Page RC, Digenis GA, Ryo UY, Cipriano A, Maniara WM, Powell ML, Chan K. Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics. J Clin Pharmacol. 1996 Mar;36(3):230-7. doi: 10.1002/j.1552-4604.1996.tb04192.x. PMID: 8690816.

3: Feldman DL, Sawyer WK, Jeune MR, Mogelesky TC, Von Linden-Reed J, Forney Prescott M. CGP 43371 paradoxically inhibits development of rabbit atherosclerotic lesions while inducing extra-arterial foam cell formation. Atherosclerosis. 2001 Feb 1;154(2):317-28. doi: 10.1016/s0021-9150(00)00492-5. PMID: 11166764.

4: Sun JX, Cipriano A, Chan K, Klibaner M, John VA. Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. J Pharm Sci. 1994 Feb;83(2):264-6. doi: 10.1002/jps.2600830231. PMID: 8169802.

5: Gibson JC, Kothari HV, Genthe TM, Lee WH, Poirier KJ, Sawyer WK, Mugrage B, Traxler P, Veenstra S, Grim M, et al. Effect of a novel series of macrocyclic hypolipidemic agents on plasma lipid and lipoprotein levels of four non-primate species. Atherosclerosis. 1992 Oct;96(2-3):147-58. doi: 10.1016/0021-9150(92)90061-k. PMID: 1466647.

6: Gibson JC, Lee WH, Piccolo JR. The ansamycins: hypolipidemic agents stimulating cholesterol removal by nonclassical mechanisms. J Lipid Res. 1994 Sep;35(9):1524-34. PMID: 7806966.

7: Maniara WM, Powell ML. Determination of the rifamycin-related hypolipidemic drug CGP 43371 in human feces, plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994 Oct 3;660(1):135-42. doi: 10.1016/0378-4347(94)00277-0. PMID: 7858706.

8: Moore DJ, Perrino PJ, Klerer CP, Robertson P. High-performance liquid chromatographic assay for two rifamycin-derived hypocholesterolemic agents in liver and biological fluids. J Chromatogr. 1993 Feb 26;612(2):310-4. doi: 10.1016/0378-4347(93)80178-7. PMID: 8468390.